Skip to content
MetabolicMoms
Menu

Essay

Perimenopause, Appetite, and Where a GLP-1 Fits

The hunger and body changes of your forties are not a character flaw. On perimenopause, shifting body composition, and where a GLP-1 fits in.

By Renée Salazar, Columnist

Evidence reviewed by Reed Ellsworth — a former pharmaceutical-industry analyst, not a treating clinician.

The body that stopped answering to the old rules

Somewhere in her forties, a woman often notices that the body she negotiated with for two decades has stopped honoring the deal. The same food, the same walk, the same restraint — and the weight settles differently, higher around the middle, more stubborn than it used to be. The instinct, drilled in by a lifetime of diet culture, is to read this as a personal failure of discipline. It is not. It is endocrinology.

What actually shifts

The menopause transition changes body composition on its own timeline. In the SWAN study, which followed women through the transition, researchers documented meaningful changes in fat and lean mass tied to the menopausal shift rather than simply to getting older1. Estrogen's decline nudges fat toward the abdomen and quietly reworks how the body handles energy. The lived experience — hungrier at odd hours, fuller belly despite unchanged habits, a metabolism that feels like it changed the locks — has a physiological basis. Naming it matters, because you cannot make a good decision about treatment while you are busy blaming yourself for a hormonal event.

Where a GLP-1 enters the picture

This is the backdrop against which many women first consider a GLP-1, and it is a reasonable one. The medications act on appetite directly: in a controlled study, semaglutide reduced energy intake and cravings and improved the sense of control over eating2 — precisely the levers perimenopause seems to move against you. And the effect is not a two-week flash. In the STEP 5 trial, semaglutide's weight effect was sustained across two years of treatment3, which matters for a transition that itself unfolds over years. For a woman watching her body change on a hormonal clock, a treatment that works on a similar horizon is at least the right shape of tool.

Holding two truths at once

None of this makes a GLP-1 the automatic answer to perimenopause. It is a serious medication, the menopause research is still catching up to the questions women are actually asking, and appetite is only one thread in a transition that also touches sleep, mood, bone, and heart. The honest position holds two truths together: your forty-something body is not betraying you out of laziness, *and* a medication is one option among several — alongside strength training, sleep, and a clinician who takes the whole transition seriously. If you do explore it, choose a provider built for ongoing, monitored care rather than a quick refill; that is exactly what our methodology rewards and what our provider rankings are meant to help you find. This essay is educational only and is not medical advice.

Frequently asked questions

Why is weight harder to manage in perimenopause?

The menopause transition shifts body composition, moving fat toward the abdomen and changing how the body handles energy, independent of aging alone. The SWAN study documented these hormone-linked changes, so the difficulty is physiological, not a lack of discipline.

Do GLP-1 medications keep working long term?

In the STEP 5 trial, semaglutide's weight effect was sustained over two years of continued treatment. The effect depends on staying on the medication, so it should be considered a long-term, monitored treatment.

References

  1. Greendale GA, et al. (2019). Changes in body composition and weight during the menopause transition. JCI Insight. https://pubmed.ncbi.nlm.nih.gov/30843880/
  2. Friedrichsen M, et al. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/33269530/
  3. Garvey WT, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/36216945/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.